Zynerba Pharmaceuticals, Inc. (ZYNE) Raised to “Overweight” at Cantor Fitzgerald
Cantor Fitzgerald upgraded shares of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) from a neutral rating to an overweight rating in a report released on Monday morning, Marketbeat reports. The brokerage currently has $17.00 price target on the stock, up from their previous price target of $4.00.
Other equities analysts have also recently issued research reports about the stock. Oppenheimer Holdings, Inc. set a $8.00 price target on shares of Zynerba Pharmaceuticals and gave the company a buy rating in a research report on Monday, August 7th. Jefferies Group LLC reiterated a buy rating and set a $32.00 price target on shares of Zynerba Pharmaceuticals in a research report on Sunday, July 9th. Maxim Group set a $32.00 price target on shares of Zynerba Pharmaceuticals and gave the company a buy rating in a research report on Monday, June 26th. Roth Capital set a $30.00 price target on shares of Zynerba Pharmaceuticals and gave the company a buy rating in a research report on Saturday, June 10th. Finally, HC Wainwright set a $30.00 price target on shares of Zynerba Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of $14.63.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) opened at 10.11 on Monday. Zynerba Pharmaceuticals has a 52-week low of $5.80 and a 52-week high of $23.57. The stock’s 50 day moving average is $7.23 and its 200-day moving average is $7.23. The company’s market cap is $134.03 million.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its quarterly earnings results on Tuesday, August 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Equities research analysts predict that Zynerba Pharmaceuticals will post ($2.42) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Zynerba Pharmaceuticals, Inc. (ZYNE) Raised to “Overweight” at Cantor Fitzgerald” was first reported by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/zynerba-pharmaceuticals-inc-zyne-raised-to-overweight-at-cantor-fitzgerald/1611961.html.
Large investors have recently bought and sold shares of the stock. Nationwide Fund Advisors bought a new stake in Zynerba Pharmaceuticals during the second quarter worth about $110,000. FNY Managed Accounts LLC bought a new stake in Zynerba Pharmaceuticals during the first quarter worth about $180,000. The Manufacturers Life Insurance Company bought a new stake in Zynerba Pharmaceuticals during the second quarter worth about $158,000. SG Americas Securities LLC bought a new stake in Zynerba Pharmaceuticals during the first quarter worth about $188,000. Finally, Bank of New York Mellon Corp boosted its stake in Zynerba Pharmaceuticals by 5.5% during the first quarter. Bank of New York Mellon Corp now owns 12,165 shares of the company’s stock worth $245,000 after acquiring an additional 635 shares in the last quarter. 34.32% of the stock is currently owned by institutional investors and hedge funds.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.